BOF 4272
Latest Information Update: 07 Aug 1995
At a glance
- Originator Otsuka Pharmaceutical
- Class Antigouts
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 07 Aug 1995 Discontinued-II for Gout in Japan (PO)
- 02 Jun 1995 Investigation in Gout in Japan (PO)